Literature DB >> 16474655

Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer.

Arun S Singh1, Cindy H Chau, Douglas K Price, William D Figg.   

Abstract

Androgens are of primary importance in the etiology of prostate cancer, and binding of the androgen dihydrotestosterone to the androgen receptor is thought to stimulate prostate growth. It has been proposed that polymorphisms within key androgen regulatory genes may contribute to an individual's risk of developing prostate cancer. Attributing single polymorphisms to complex, late-onset, chronic diseases such as prostate cancer is probably not feasible, but identification of genes that increase risk will contribute to larger-scale multigenic risk assessment. Here, we review the current status of our knowledge of associations between important androgen regulatory gene polymorphisms and prostate cancer risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16474655     DOI: 10.1038/ncpuro0091

Source DB:  PubMed          Journal:  Nat Clin Pract Urol        ISSN: 1743-4270


  7 in total

1.  Low serum testosterone levels are predictive of prostate cancer.

Authors:  Luigi Mearini; Alessandro Zucchi; Elisabetta Nunzi; Tommaso Villirillo; Vittorio Bini; Massimo Porena
Journal:  World J Urol       Date:  2011-11-09       Impact factor: 4.226

2.  Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.

Authors:  Douglas K Price; Cindy H Chau; Cathee Till; Phyllis J Goodman; Robin J Leach; Teresa L Johnson-Pais; Ann W Hsing; Ashraful Hoque; Howard L Parnes; Jeannette M Schenk; Catherine M Tangen; Ian M Thompson; Juergen K V Reichardt; William D Figg
Journal:  Cancer       Date:  2016-05-10       Impact factor: 6.860

3.  Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy.

Authors:  Takeshi Yamada; Masashi Nakayama; Tomohito Shimizu; Shinpei Nonen; Yasutomo Nakai; Kazuo Nishimura; Yasushi Fujio; Akihiko Okuyama; Junichi Azuma; Norio Nonomura
Journal:  Int J Clin Oncol       Date:  2012-06-21       Impact factor: 3.402

4.  Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.

Authors:  Aruna V Sarma; Rodney L Dunn; Leslie A Lange; Anna Ray; Yunfei Wang; Ethan M Lange; Kathleen A Cooney
Journal:  Prostate       Date:  2008-02-15       Impact factor: 4.104

5.  Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of korean men.

Authors:  Bo Sung Shin; Eu Chang Hwang; Chang Min Im; Sun-Ouck Kim; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park; Soo Bang Ryu
Journal:  Korean J Urol       Date:  2010-12-21

6.  A novel model to predict positive prostate biopsy based on serum androgen level.

Authors:  Takeshi Ujike; Motohide Uemura; Atsunari Kawashima; Akira Nagahara; Kazutoshi Fujita; Yasushi Miyagawa; Norio Nonomura
Journal:  Endocr Relat Cancer       Date:  2017-10-18       Impact factor: 5.678

Review 7.  Genotyping the High Altitude Mestizo Ecuadorian Population Affected with Prostate Cancer.

Authors:  Andrés López-Cortés; Alejandro Cabrera-Andrade; Carolina Salazar-Ruales; Ana Karina Zambrano; Santiago Guerrero; Patricia Guevara; Paola E Leone; César Paz-Y-Miño
Journal:  Biomed Res Int       Date:  2017-06-08       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.